AIMS/HYPOTHESIS: The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+) FDRs) of type 1 diabetic patients. METHODS: Hyperglycaemic clamps were performed in 17 non-diabetic IA-2A(+) FDRs aged 14 to 33 years and in 21 matched healthy volunteers (HVs). Insulin and C-peptide responses were measured during the first (5-10 min) and second (120-150 min) release phase, and after glucagon injection (150-160 min). Clamp-induced C-peptide release was compared with C-peptide release during OGTT. RESULTS: Seven (41%) FDRs developed diabetes 3-63 months after their initial clamp test. In all phases they had lower C-peptide responses than non-progressors (p < 0.05) and HVs (p < 0.002). All five FDRs with low first-phase release also had low second-phase release and developed diabetes 3-21 months later. Two of seven FDRs with normal first-phase but low second-phase release developed diabetes after 34 and 63 months, respectively. None of the five FDRs with normal C-peptide responses in all test phases has developed diabetes so far (follow-up 56 to 99 months). OGTT-induced C-peptide release also tended to be lower in progressors than in non-progressors or HVs, but there was less overlap in results between progressors and the other groups using the clamp. CONCLUSIONS/ INTERPRETATION: Clamp-derived functional variables stratify risk of diabetes in IA-2A(+) FDRs and may more consistently identify progressors than OGTT-derived variables. A low first-phase C-peptide response specifically predicts impending diabetes while a low second-phase response may reflect an earlier disease stage. TRIAL REGISTRATION: ClinicalTrials.gov NCT00654121 FUNDING: The insulin trial was financially supported by Novo Nordisk Pharma nv.
AIMS/HYPOTHESIS: The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+) FDRs) of type 1 diabeticpatients. METHODS: Hyperglycaemic clamps were performed in 17 non-diabetic IA-2A(+) FDRs aged 14 to 33 years and in 21 matched healthy volunteers (HVs). Insulin and C-peptide responses were measured during the first (5-10 min) and second (120-150 min) release phase, and after glucagon injection (150-160 min). Clamp-induced C-peptide release was compared with C-peptide release during OGTT. RESULTS: Seven (41%) FDRs developed diabetes 3-63 months after their initial clamp test. In all phases they had lower C-peptide responses than non-progressors (p < 0.05) and HVs (p < 0.002). All five FDRs with low first-phase release also had low second-phase release and developed diabetes 3-21 months later. Two of seven FDRs with normal first-phase but low second-phase release developed diabetes after 34 and 63 months, respectively. None of the five FDRs with normal C-peptide responses in all test phases has developed diabetes so far (follow-up 56 to 99 months). OGTT-induced C-peptide release also tended to be lower in progressors than in non-progressors or HVs, but there was less overlap in results between progressors and the other groups using the clamp. CONCLUSIONS/ INTERPRETATION: Clamp-derived functional variables stratify risk of diabetes in IA-2A(+) FDRs and may more consistently identify progressors than OGTT-derived variables. A low first-phase C-peptide response specifically predicts impending diabetes while a low second-phase response may reflect an earlier disease stage. TRIAL REGISTRATION: ClinicalTrials.gov NCT00654121 FUNDING: The insulin trial was financially supported by Novo Nordisk Pharma nv.
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: F K Gorus; P Goubert; C Semakula; C L Vandewalle; J De Schepper; A Scheen; M R Christie; D G Pipeleers Journal: Diabetologia Date: 1997-01 Impact factor: 10.122
Authors: I Truyen; J De Grijse; C Van Schravendijk; D De Smet; K Decochez; E Vandemeulebroucke; M Giri; B Keymeulen; C Mathieu; L Van Gaal; P De Pauw; I Weets; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2007-08-09 Impact factor: 10.122
Authors: Annelien Van Dalem; Simke Demeester; Eric V Balti; Katelijn Decochez; Ilse Weets; Evy Vandemeulebroucke; Ursule Van de Velde; An Walgraeve; Nicole Seret; Christophe De Block; Johannes Ruige; Pieter Gillard; Bart Keymeulen; Daniel G Pipeleers; Frans K Gorus Journal: Diabetologia Date: 2015-09-26 Impact factor: 10.122
Authors: E Mbunwe; B J Van der Auwera; I Weets; P Van Crombrugge; L Crenier; M Coeckelberghs; N Seret; K Decochez; E Vandemeulebroucke; P Gillard; B Keymeulen; C van Schravendijk; J M Wenzlau; J C Hutton; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2013-05-28 Impact factor: 10.122
Authors: J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122
Authors: F K Gorus; E V Balti; I Vermeulen; S Demeester; A Van Dalem; O Costa; H Dorchy; S Tenoutasse; T Mouraux; C De Block; P Gillard; K Decochez; J M Wenzlau; J C Hutton; D G Pipeleers; I Weets Journal: Clin Exp Immunol Date: 2013-01 Impact factor: 4.330
Authors: Eric Mbunwe; Bart J Van der Auwera; Ilse Vermeulen; Simke Demeester; Annelien Van Dalem; Eric V Balti; Sara Van Aken; Luc Derdelinckx; Harry Dorchy; Jean De Schepper; Chris van Schravendijk; Janet M Wenzlau; John C Hutton; Daniël Pipeleers; Ilse Weets; Frans K Gorus Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: Simke Demeester; Bart Keymeulen; Leonard Kaufman; Annelien Van Dalem; Eric V Balti; Ursule Van de Velde; Patrick Goubert; Katrijn Verhaeghen; Howard W Davidson; Janet M Wenzlau; Ilse Weets; Daniel G Pipeleers; Frans K Gorus Journal: Diabetes Care Date: 2015-01-12 Impact factor: 19.112
Authors: Annelien Van Dalem; Simke Demeester; Eric V Balti; Bart Keymeulen; Pieter Gillard; Bruno Lapauw; Christophe De Block; Pascale Abrams; Eric Weber; Ilse Vermeulen; Pieter De Pauw; Daniël Pipeleers; Ilse Weets; Frans K Gorus Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: Pieter Gillard; Robert Hilbrands; Ursule Van de Velde; Zhidong Ling; Da Hae Lee; Ilse Weets; Frans Gorus; Christophe De Block; Leonard Kaufman; Chantal Mathieu; Daniel Pipeleers; Bart Keymeulen Journal: Diabetes Care Date: 2013-09-16 Impact factor: 19.112